10-year follow-up of the prospective H96 trial by the LYSA / SFGM-TC study group: risk-adapted single or tandem autologous stem-cell transplantation strategy remains appropriate for first relapsed or refractory Hodgkin lymphoma with long-term follow-up

245 Hodgkin lymphoma patients
H96 trial by the LYSA / SFGM-TC study group

Intermediate-risk group (n=95)
one risk factor at first relapse*
single autologous stem-cell transplantation

Poor-risk group (n=150)
primary refractory Hodgkin lymphoma (n=77)
or ≥2 risk factors at first relapse* (n=73)
tandem autologous stem-cell transplantation

*relapse < 12 months, stage III or IV at relapse and/or relapse in a previously irradiated site

10-year follow-up

64% Freedom from second failure (intent-to-treat analysis) 41%
70% Overall Survival (intent-to-treat analysis) 47%

Sibon et al., Haematologica, 2016